Raxatrigine - 10mM in DMSO , Sodium channel protein type IX alpha subunit blocker, CAS No.934240-30-9, Sodium channel protein type IX alpha subunit blocker
Raxatrigine - 10mM in DMSO , Sodium channel protein type IX alpha subunit blocker, CAS No.934240-30-9, Sodium channel protein type IX alpha subunit blocker
Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor .
In Vitro
Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. Raxatrigine (GSK-1014802) received orphan-drug designation from the US Food and Drug Administration in July 2013. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:Sodium channel blocker
仕様
仕様と純度
10mM in DMSO
生化学的・生理学的メカニズム
Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor .
保管条件
Store at -80°C
入荷
Dry ice packs + Cold packs
この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。
アクションタイプ
BLOCKER
作用メカニズム
Sodium channel protein type IX alpha subunit blocker
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
